Article Sidebar
Published:
Dec 31, 2023Keywords:
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All materials published in the Babcock University Medical Journal (BUMJ) are protected by the Copyrights Laws of Nigeria. The Authors reserves copyright of their published articles but gives all the users (Authors, Readers, and Researchers) free access to all materials published online under the provisions of the Creative Commons Attribution Non-Commercial 4.0 License. However, permissions are granted to copy, use, and distribute the contents only for non-commercial but academic and scientific purposes with the proviso that the source of the content is appropriately cited and credited.
Main Article Content
Anti-craving Property of Chlorpromazine in Pentazocine addiction among sickle cell disease patients: A Case Series
Ogungbemi AO
Abstract
Background: Opioids are useful in the management of vaso-occlusive crisis among Sickle Cell Disease patients; however, there is a need to search for drugs that can ameliorate the withdrawal symptoms without causing further dependence.
Case presentations: Three patients living with Sickle cell disease abusing Pentazocine were managed with Tab Chlorpromazine 100mg twice daily for three weeks and had a significant reduction in the level of craving and also experienced improved sleep. Chlorpromazine demonstrates a high affinity for dopamine (DA) receptors and acts as a receptor antagonist by inhibiting adenylate cyclase activity.
Conclusion: Chlorpromazine was found to be useful in the management of cravings associated with Pentazocine addiction.
